874
Views
4
CrossRef citations to date
0
Altmetric
Research Articles

Prepontine cisternal routine for intrathecal targeted drug delivery in craniofacial cancer pain treatment: technical note

, , , , &
Pages 3213-3217 | Received 22 Aug 2022, Accepted 04 Oct 2022, Published online: 19 Oct 2022

References

  • Appelgren L, Janson M, Nitescu P, Curelaru I. (1996). Continuous intracisternal and high cervical intrathecal bupivacaine analgesia in refractory head and neck pain. Anesthesiology 84:256–72.
  • Baker L, Balls J, Regnard C, Pridie A. (2007). Cervical intrathecal analgesia for head and neck/upper limb cancer pain: six case reports. Palliat Med 21:543–5.
  • Benyamin R, Trescot AM, Datta S, et al. (2008). Opioid complications and side effects. Pain Physician 11:S105–S120.
  • Dong DS, Yu X, Wan CF, et al. (2017). Efficacy of short-term spinal cord stimulation in acute/subacute zoster-related pain: a retrospective study. Pain Physician 20:E633–E645.
  • Dupoiron D. (2020). Targeted drug delivery (intrathecal and intracranial) for treatment of facial pain. Prog Neurol Surg 35:181–93.
  • Hayek SM, Sweet JA, Miller JP, Sayegh RR. (2016). Successful management of corneal neuropathic pain with intrathecal targeted drug delivery. Pain Med 17:1302–7.
  • Lundborg C, Dahm P, Nitescu P, Biber B. (2009). High intrathecal bupivacaine for severe pain in the head and neck. Acta Anaesthesiol Scand 53:908–13.
  • Matsuno H, Rhoton AL, Jr, Peace D. (1988). Microsurgical anatomy of the posterior fossa cisterns. Neurosurgery 23:58–80.
  • Moman RN, Rogers JM, Pittelkow TP. (2019). High cervical intrathecal targeted drug delivery: a case report of refractory oropharyngeal cancer pain. Case Rep Oncol Med 2019:2098921.
  • Narváez MJ, Bulnes JM, Elena JM, et al. (2002). Programmable pump for the administration of morphine in the cisterna magna. A new approach. Neuromodulation 5:145–9.
  • Pak D, Hung J. (2019). Gastrointestinal cancer pain. In: Gulati A, Puttanniah V, Bruel B, Rosenberg W, Hung J, eds. Essentials of interventional cancer pain management. Cham: Springer.
  • Schultz DM, Orhurhu V, Khan F, et al. (2020). Patient satisfaction following intrathecal targeted drug delivery for benign chronic pain: results of a single-center survey study. Neuromodulation 23:1009–17.
  • Sylvester RK, Lindsay SM, Schauer C. (2004). The conversion challenge: from intrathecal to oral morphine. Am J Hosp Palliat Care 21:143–7.
  • Taren JA, Kahn EA. (1962). Anatomic pathways related to pain in face and neck. J Neurosurg 19:116–21.
  • van Dongen RT, Crul BJ, van Egmond J. (1999). Intrathecal coadministration of bupivacaine diminishes morphine dose progression during long-term intrathecal infusion in cancer patients. Clin J Pain 15:166–72.
  • Wang Q, Chen C, Guo G, et al. (2021). A prospective study to examine the association of the foramen ovale size with intraluminal pressure of pear-shaped balloon in percutaneous balloon compression for trigeminal neuralgia. Pain Ther 10:1439–50.
  • Zhou H, Han R, Chen L, et al. (2022). Effect of implantable electrical nerve stimulation on cortical dynamics in patients with herpes zoster-related pain: a prospective pilot study. Front Bioeng Biotechnol 10:862353.
  • Zou D, Zhang W, Wang Y. (2021). Prepontine cistern intrathecal targeted drug delivery for cancer-related craniofacial pain. Pain Med 22:3112–4.